Published on 13 Feb 2024 on GuruFocus.com via Yahoo Finance
Vistagen Therapeutics Inc (VTGN) Reports Fiscal 2024 Q3 Results: A Closer Look at Financials ...
Research and Development Expenses: Decreased to $4.5 million from $6.9 million in the same quarter last year.General and Administrative Expenses: Increased to $3.8 million from $3.1 million year-over-year.Net Loss: Improved to $6.3 million from a net loss of $9.8 million in the prior year's quarter.Cash Position: Strong with $126.6 million in cash and cash equivalents as of December 31, 2023.Stock Issuance: 27,029,731 shares of common stock and 3,577,240 pre-funded warrants outstanding as of February 12, 2024.
Warning! GuruFocus has detected 4 Warning Signs with VTGN.